Progress in Neurotherapeutics and Neuropsychopharmacology最新文献_第3页

AVP-923 as a Novel Treatment for Pseudobulbar Affect in ALS AVP-923治疗ALS假性球损伤的新方法

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2006-02-15 DOI: 10.1017/S1748232105000091

L. Pope

引用次数: 2

Modafinil for the Treatment of Fatigue in Multiple Sclerosis 莫达非尼治疗多发性硬化症疲劳

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2006-02-15 DOI: 10.1017/S1748232105000042

B. Stankoff, C. Lubetzki, M. Clanet

引用次数: 0

Treating Migraine Attacks ASAP: Concept and Methodological Issues 尽快治疗偏头痛:概念和方法问题

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2006-02-15 DOI: 10.1017/S1748232105000066

N. Wiendels, M. Ferrari

引用次数: 0

Selegiline in the Treatment of Negative Symptoms of Schizophrenia 斯来吉兰治疗精神分裂症阴性症状的疗效观察

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2006-02-15 DOI: 10.1017/S1748232105000121

Allison Lin, J. Bodkin

引用次数: 0

Liquid Fluoxetine versus Placebo for Repetitive Behaviors in Childhood Autism 液体氟西汀与安慰剂对儿童自闭症重复行为的影响

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 1900-01-01 DOI: 10.1017/S1748232105000108

E. Hollander, E. Swanson, E. Anagnostou, Ann T. Phillips, W. Chaplin, S. Wasserman

引用次数: 3

Introduction to Neurotherapeutics and Neuropsychopharmacology 神经治疗学和神经精神药理学导论

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 1900-01-01 DOI: 10.1017/S1748232105000029

J. Cummings

{"title":"Introduction to Neurotherapeutics and Neuropsychopharmacology","authors":"J. Cummings","doi":"10.1017/S1748232105000029","DOIUrl":"https://doi.org/10.1017/S1748232105000029","url":null,"abstract":"In recent years there has been tremendous progress in advancing new treatments for neurologic and psychiatric illnesses. New agents have emerged for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, schizophrenia, bipolar illness, depression, and substance abuse disorders. Advances in understanding of basic pathophysiology and molecular biology of brain disorders have led to increasingly sophisticated target identification that guides drug development. Advances in the basic neuroscience and disease mechanisms have been particularly obvious in the neurologic disorders where there is an ever improving understanding of the underlying mechanisms of brain function and brain disease. Progress in neurotherapeutics has occurred in concert with progress in basic science methodologies, neuroimaging, clinical trial design, and trial analysis. There is an increasing enthusiasm for clinical trials that provide highly credible data with which to guide evidence-based medicine. The United States Food and Drug Administration (US FDA) requires a close link between the clinical trial population tested and the specific indication for which the agent will be approved. This contributes to the proliferation of clinical trials, as industry sponsors of trials seek to expand the populations for which their products are indicated. An increasing number of patients and physicians are involved in clinical trials. Advancing clinical trial methodology has itself become a major endeavor.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129834663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial 在一项试验中测试治疗精神分裂症的多种新机制

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 1900-01-01 DOI: 10.1017/S174823210500011X

H. Meltzer

引用次数: 1